| Primary |
| Drug Use For Unknown Indication |
100.0% |
|
| Talipes |
66.7% |
| International Normalised Ratio Increased |
33.3% |
|
| Secondary |
| Product Used For Unknown Indication |
24.5% |
| Drug Use For Unknown Indication |
19.5% |
| Pustular Psoriasis |
9.0% |
| Hypertension |
6.5% |
| Pneumonia |
5.4% |
| Bronchitis |
4.7% |
| Pyrexia |
4.3% |
| Non-hodgkin's Lymphoma |
4.0% |
| Diabetes Mellitus |
3.2% |
| Cardiac Failure Congestive |
2.2% |
| Pain |
2.2% |
| Atrial Fibrillation |
1.8% |
| Depression |
1.8% |
| Myocardial Ischaemia |
1.8% |
| Urethritis |
1.8% |
| Arthritis |
1.4% |
| Blood Pressure Abnormal |
1.4% |
| Gout |
1.4% |
| Hypercholesterolaemia |
1.4% |
| Muscle Spasms |
1.4% |
|
| Rhabdomyolysis |
17.1% |
| Tachycardia |
12.2% |
| Jaundice Cholestatic |
9.8% |
| Pneumonia |
7.3% |
| Respiratory Failure |
7.3% |
| Cytolytic Hepatitis |
4.9% |
| Hepatic Enzyme Increased |
4.9% |
| Serotonin Syndrome |
4.9% |
| Talipes |
4.9% |
| Acquired Haemophilia |
2.4% |
| Acute Myocardial Infarction |
2.4% |
| Alanine Aminotransferase Increased |
2.4% |
| Aplastic Anaemia |
2.4% |
| Clostridium Difficile Colitis |
2.4% |
| Congestive Cardiomyopathy |
2.4% |
| Drug Interaction |
2.4% |
| Grand Mal Convulsion |
2.4% |
| Hypoalbuminaemia |
2.4% |
| Infection |
2.4% |
| Lung Infiltration |
2.4% |
|
| Concomitant |
| Drug Use For Unknown Indication |
22.8% |
| Hiv Infection |
19.8% |
| Product Used For Unknown Indication |
9.5% |
| Prophylaxis |
6.9% |
| Antifungal Prophylaxis |
4.4% |
| Mycobacterium Avium Complex Infection |
4.1% |
| Sepsis |
3.6% |
| Cancer Pain |
3.3% |
| Pneumonia |
3.1% |
| Rash |
2.7% |
| Infection Prophylaxis |
2.4% |
| Cytomegalovirus Infection |
2.3% |
| Antiviral Prophylaxis |
2.0% |
| Constipation |
2.0% |
| Prostate Cancer Metastatic |
2.0% |
| Cough |
1.9% |
| Nausea |
1.9% |
| Prophylaxis Against Gastrointestinal Ulcer |
1.8% |
| Prophylaxis Against Graft Versus Host Disease |
1.8% |
| Bone Marrow Conditioning Regimen |
1.7% |
|
| Vomiting |
20.7% |
| Pneumonia |
8.6% |
| Sepsis |
7.8% |
| Pulmonary Embolism |
6.0% |
| Pyrexia |
6.0% |
| Meningitis Cryptococcal |
5.2% |
| Respiratory Arrest |
5.2% |
| Urinary Retention |
5.2% |
| Weight Decreased |
4.3% |
| Interstitial Lung Disease |
3.4% |
| Prostate Cancer |
3.4% |
| Renal Failure Acute |
3.4% |
| Blood Immunoglobulin E Increased |
2.6% |
| Cough |
2.6% |
| Onychoclasis |
2.6% |
| Osteonecrosis |
2.6% |
| Pneumonitis |
2.6% |
| Product Quality Issue |
2.6% |
| Shock |
2.6% |
| Thrombocytopenia |
2.6% |
|
| Interacting |
| Pneumonia |
15.9% |
| Atrial Fibrillation |
14.6% |
| Renal Failure Chronic |
9.8% |
| Anaemia Haemolytic Autoimmune |
7.3% |
| Helicobacter Gastritis |
7.3% |
| Gastritis |
6.1% |
| Blood Cholesterol |
4.9% |
| Hypertension |
4.9% |
| Thyroid Disorder |
4.9% |
| Ill-defined Disorder |
3.7% |
| Neuroborreliosis |
3.7% |
| Respiratory Tract Infection |
3.7% |
| Bronchitis |
2.4% |
| Upper Respiratory Tract Infection |
2.4% |
| Urinary Tract Infection |
2.4% |
| Hyperlipidaemia |
1.2% |
| Hyperprolactinaemia |
1.2% |
| Hyperuricaemia |
1.2% |
| Prophylaxis Against Gastrointestinal Ulcer |
1.2% |
| Transient Ischaemic Attack |
1.2% |
|
| Drug Interaction |
27.8% |
| Rhabdomyolysis |
22.2% |
| Venoocclusive Liver Disease |
16.7% |
| Clostridium Difficile Colitis |
11.1% |
| Haemorrhage |
5.6% |
| Occult Blood Positive |
5.6% |
| Raynaud's Phenomenon |
5.6% |
| Vomiting |
5.6% |
|
